Category: UNCATEGORIZED

03 Oct 2019

Notion Capital launches new $150M fund aimed at European B2B tech

Notion Capital today announces a new $150M fund in a bid to bolster its claim to being the go-to investor for European B2B tech.

Launched ten years ago after the $700M exit of MessageLabs by co-founders Ben and Jos White, this new fourth fund will continue its previous focus on Series A SaaS and enterprise tech, but will now come with an increased focus on cybersecurity, automation and marketplaces. Notion now has $500M under management and over 50 investments. Its portfolio includes several European unicorns, including Tradeshift, GoCardless Unbabel, Paddle, CurrencyCloud, Duedil, Mews Systems and others.

Commenting, partner Stephen Chandler said: “When we founded Notion in 2009, we felt there was a mouth-watering, once-in-a-lifetime opportunity to help transform an industry and create a huge amount of value along the way. Having built the largest EU SaaS exit, we firmly believed that SaaS, as a fundamentally better way of delivering software, was going to be transformational and that we had a unique perspective.”

He also said: “Notion is the only post-seed VC in Europe started by B2B founders. That means a culture of entrepreneurial empathy and investigating the whys and hows, instead of just cold KPIs. We ran and built one SaaS company for ten years and have subsequently invested in and worked with 60+ SaaS companies over the next ten.”

In May of this year, Notion launched Included, a VC fellowship program, to increase the number of underrepresented communities within the venture capital industry and the diversity of deal flow.

It has now had more than 1,500 applications for 30 places on the 12-month fellowship which starts this month. Whilst Notion was the pioneer behind this initiative, the program is now widely supported and funded by a wide group of European VCs and other sponsors.

03 Oct 2019

In a new filing, the venture firm Mithril Capital says it has been under assault by its former general counsel

It’s been a strange year for Mithril Capital Management, the venture firm cofounded in 2012 by Peter Thiel and his longtime associate Ajay Royan. Though Mithril enjoyed its biggest exit to date in February, when Johnson & Johnson agreed to pay $3.4 billion — plus another potential $2.35 billion in payments  — for the surgical robotics company Auris Robotics, the firm has been characterized in news reports by Recode as in a complete state of disarray and, more recently, for reportedly being investigated by the FBI for financial misconduct.

Mithril is now drawing a line from those stories to former employee Crystal McKellar, who’d joined Mithril from the outset as its general counsel though she also long held the title of managing director.

According to a new legal petition filed in Texas, where Mithril moved its headquarters from San Francisco earlier this year, McKellar has, over many months, staged a multi-pronged campaign to disparage Mithril and Royan specifically in order to attract its investors to a new, separate venture firm that she has founded called Anathem Ventures.

Certainly, the filing makes for strange reading. Among its assertions is that McKellar, who has told friends she was fired from the firm earlier this year, signed a separation agreement with Mithril that included “substantial severance,” a “courtesy title” that it says she asked for, and a consulting agreement. But it goes on to say that “almost immediately after signing them, Ms. McKellar began to materially breach these agreements.” Specifically, it says, she promised not to engage in any business that’s competitive with Mithril, including any business relating to any portfolio investments that Mithril has ever considered, yet she “completed her signature pages, completing her investment” of $50,000 in one of these companies “mere minutes” after emailing Royan to tell him she planned to invest and offering him the right of first refusal.

It also accuses her of accepting consulting fees from Mithril while taking on jobs that put her in direct competition with the firm, including becoming a managing partner at a hedge fund, Signum, as well as launching her own new venture, Anathen Ventures, in July.

And the complaint accuses McKellar of retaining possession for too long of her Mithril-issued mobile phone and laptop, saying it is “taking the appropriate steps to verify the provenance and integrity of its devices, and to protect their contents.”

Still, the document — technically an “application for temporary and permanent injunctive relief” — most surprisingly says McKellar stirred “discord” with Mithril’s relationships with its investors, financial partners, and service providers.

In one instance, Mithril says,  its auditor was sent a letter from a “nameless investor” that “disparaged Mr. Royan and the firm” by “falsely accusing Mr. Royan of ‘lying'” publicly about whether he had ever waived some of the firm’s management fees. It further accuses her of authoring “false letters” to senior executives at a major Mithril company in New England, saying it determined she had authored the letters through “expert forensic analysis.”

Why McKellar was forced out of the firm isn’t clear, though Recode has reported that numerous members of Mithril’s investment staff have been shown the door over the years, and that this downsizing has troubled cofounder, Thiel, who tends to work collaboratively with others and who has engendered loyalty as a result.

Indeed, Royan was previously a managing director at Thiel’s earlier hedge fund, Clarium Capital, as were a handful of early Mithril employees. Today, Mithril is largely run by Royan; his sister Anuja Royan, who is the firm’s CFO; and Paul Leggett, a managing director who handles much of the firm’s day-to-day operations while Royan is seemingly more focused on the bigger picture. The firm has also hired several people since moving to Austin.

Asked for comment on the filing, Royan suggested he will let the document speak for itself.

Meanwhile, reached via email, McKellar writes that she “been served with the suit so I haven’t seen the actual allegations, but those sound pretty loony.”

She added in her statement: “This isn’t about me.  This is about what’s going on at Mithril.  This is about Mithril’s investors, who are families, foundations, and charities that help the most vulnerable Americans, and the pension funds that permit our public servants to retire with dignity. These investors placed their trust and money in promises that were made by Mithril.  I left Mithril earlier this year when it became clear to me that Mithril’s leadership was lying to its investors and that the promises it had made were not going to be kept.”

Pressed for details, McKellar said she couldn’t comment further, though she did note that her role with Signum did not violate her consulting agreement with Mithril, which precluded her from performing “advisory services or other services for, or provide consulting to, any venture capital firm, private equity firm, or any company that invests in, or manages funds that invests in, venture capital or private equity funds …”

In the meantime, it remains unclear what promises to investors have not been kept, outside of the changing composition of the team, particularly as Mithril was relocating to Texas. (We gather that most of the firm’s employees did not want to move, so wound up leaving the firm for other roles after receiving extended severance packages. It is also our impression, having talked with various employees of Mithril over the years, that the firm’s economics greatly favor Royan.)

Though certainly cause for concern, the firm, whose two funds both have 12-year investing horizons, seems to be performing.  A knowledgeable source says Auris’s acquisition could potentially produce a $950 million windfall for Mithril if it hits certain milestones.

Most of that return belongs to the firm’s debut fund, which had closed with $540 million, with a much smaller percentage returned to investors in the second fund, a $740 million vehicle that was closed in early 2017.

Mithril, which is known for making more concentrated bets in fewer companies, owned 15 percent of Auris when it was snapped up. The firm also has sizable stakes in the intelligence software company Palantir; in Adamab, a New Hampshire-based antibody drug discovery shop; and, in a very recent bet, Glance, which is a subsidiary of the Indian mobile ad business firm InMobi and that announced $45 million in funding last month from Mithril.

As for that reported FBI investigation, we haven’t been able to confirm that there’s anything more to it than an open dialogue between the agency and Mithril, which last month told Recode that such inquiries were the result of a “foiled plot by a self-serving ex-employees.”

Today, at least, it’s much clearer who, exactly, Mithril is looking to blame.

We’re guessing there will be much more to this story soon.

03 Oct 2019

In a new filing, the venture firm Mithril Capital says it has been under assault by its former general counsel

It’s been a strange year for Mithril Capital Management, the venture firm cofounded in 2012 by Peter Thiel and his longtime associate Ajay Royan. Though Mithril enjoyed its biggest exit to date in February, when Johnson & Johnson agreed to pay $3.4 billion — plus another potential $2.35 billion in payments  — for the surgical robotics company Auris Robotics, the firm has been characterized in news reports by Recode as in a complete state of disarray and, more recently, for reportedly being investigated by the FBI for financial misconduct.

Mithril is now drawing a line from those stories to former employee Crystal McKellar, who’d joined Mithril from the outset as its general counsel though she also long held the title of managing director.

According to a new legal petition filed in Texas, where Mithril moved its headquarters from San Francisco earlier this year, McKellar has, over many months, staged a multi-pronged campaign to disparage Mithril and Royan specifically in order to attract its investors to a new, separate venture firm that she has founded called Anathem Ventures.

Certainly, the filing makes for strange reading. Among its assertions is that McKellar, who has told friends she was fired from the firm earlier this year, signed a separation agreement with Mithril that included “substantial severance,” a “courtesy title” that it says she asked for, and a consulting agreement. But it goes on to say that “almost immediately after signing them, Ms. McKellar began to materially breach these agreements.” Specifically, it says, she promised not to engage in any business that’s competitive with Mithril, including any business relating to any portfolio investments that Mithril has ever considered, yet she “completed her signature pages, completing her investment” of $50,000 in one of these companies “mere minutes” after emailing Royan to tell him she planned to invest and offering him the right of first refusal.

It also accuses her of accepting consulting fees from Mithril while taking on jobs that put her in direct competition with the firm, including becoming a managing partner at a hedge fund, Signum, as well as launching her own new venture, Anathen Ventures, in July.

And the complaint accuses McKellar of retaining possession for too long of her Mithril-issued mobile phone and laptop, saying it is “taking the appropriate steps to verify the provenance and integrity of its devices, and to protect their contents.”

Still, the document — technically an “application for temporary and permanent injunctive relief” — most surprisingly says McKellar stirred “discord” with Mithril’s relationships with its investors, financial partners, and service providers.

In one instance, Mithril says,  its auditor was sent a letter from a “nameless investor” that “disparaged Mr. Royan and the firm” by “falsely accusing Mr. Royan of ‘lying'” publicly about whether he had ever waived some of the firm’s management fees. It further accuses her of authoring “false letters” to senior executives at a major Mithril company in New England, saying it determined she had authored the letters through “expert forensic analysis.”

Why McKellar was forced out of the firm isn’t clear, though Recode has reported that numerous members of Mithril’s investment staff have been shown the door over the years, and that this downsizing has troubled cofounder, Thiel, who tends to work collaboratively with others and who has engendered loyalty as a result.

Indeed, Royan was previously a managing director at Thiel’s earlier hedge fund, Clarium Capital, as were a handful of early Mithril employees. Today, Mithril is largely run by Royan; his sister Anuja Royan, who is the firm’s CFO; and Paul Leggett, a managing director who handles much of the firm’s day-to-day operations while Royan is seemingly more focused on the bigger picture. The firm has also hired several people since moving to Austin.

Asked for comment on the filing, Royan suggested he will let the document speak for itself.

Meanwhile, reached via email, McKellar writes that she “been served with the suit so I haven’t seen the actual allegations, but those sound pretty loony.”

She added in her statement: “This isn’t about me.  This is about what’s going on at Mithril.  This is about Mithril’s investors, who are families, foundations, and charities that help the most vulnerable Americans, and the pension funds that permit our public servants to retire with dignity. These investors placed their trust and money in promises that were made by Mithril.  I left Mithril earlier this year when it became clear to me that Mithril’s leadership was lying to its investors and that the promises it had made were not going to be kept.”

Pressed for details, McKellar said she couldn’t comment further, though she did note that her role with Signum did not violate her consulting agreement with Mithril, which precluded her from performing “advisory services or other services for, or provide consulting to, any venture capital firm, private equity firm, or any company that invests in, or manages funds that invests in, venture capital or private equity funds …”

In the meantime, it remains unclear what promises to investors have not been kept, outside of the changing composition of the team, particularly as Mithril was relocating to Texas. (We gather that most of the firm’s employees did not want to move, so wound up leaving the firm for other roles after receiving extended severance packages. It is also our impression, having talked with various employees of Mithril over the years, that the firm’s economics greatly favor Royan.)

Though certainly cause for concern, the firm, whose two funds both have 12-year investing horizons, seems to be performing.  A knowledgeable source says Auris’s acquisition could potentially produce a $950 million windfall for Mithril if it hits certain milestones.

Most of that return belongs to the firm’s debut fund, which had closed with $540 million, with a much smaller percentage returned to investors in the second fund, a $740 million vehicle that was closed in early 2017.

Mithril, which is known for making more concentrated bets in fewer companies, owned 15 percent of Auris when it was snapped up. The firm also has sizable stakes in the intelligence software company Palantir; in Adamab, a New Hampshire-based antibody drug discovery shop; and, in a very recent bet, Glance, which is a subsidiary of the Indian mobile ad business firm InMobi and that announced $45 million in funding last month from Mithril.

As for that reported FBI investigation, we haven’t been able to confirm that there’s anything more to it than an open dialogue between the agency and Mithril, which last month told Recode that such inquiries were the result of a “foiled plot by a self-serving ex-employees.”

Today, at least, it’s much clearer who, exactly, Mithril is looking to blame.

We’re guessing there will be much more to this story soon.

03 Oct 2019

Africa Roundup: CcHub’s iHub acquisition, Andela’s $50M run-rate and layoffs, Transsion’s IPO

Two of Africa’s powerhouse tech incubators joined forces in September. Nigerian innovation center and seed-fund CcHub acquired Nairobi based iHub.

The purchase amount was undisclosed, but CcHub will finance the deal out of its real-estate project to build a new 10-story HQ in Lagos, CcHub CEO Bosun Tijani told TechCrunch.

Details are emerging on how the two entities will operate together, but Tijani noted some degree of autonomy. The names — CcHub and iHub — will remain the same. Tijani is now co-CEO of both organizations.

Nekesa Were continues as iHub managing director. And iHub’s existing programs will remain, with CcHub extending to Kenya some of its existing activities in education, healthcare and governance.

CcHub will also use the iHub addition to expand the investment scope of its Growth Capital Fund.

The acquisition brings together two of Africa’s most powerful tech hubs by membership networks, volume of programs, startups incubated, and global visibility. CcHub and iHub visitors and partnerships span Zuckerberg, Mayer, Facebook, Google, and several African governments.

There’ll be a lot to cover on how this merger shapes up. At a high level, for now, the CcHub-iHub union creates a direct innovation link between two of Africa’s most active markets for VC and startup formation — Nigeria and Kenya .

Africa-focused tech talent accelerator Andela  announced cuts of 400 junior engineers across Kenya,  Uganda and Nigeria just as the startup released first-time earnings figures indicating it will surpass $50 million in revenues for 2019.

On the disjointed news, Andela CEO told TechCrunch the layoffs were due to a shift in market demand for the startup’s more senior developers.

Andela’s client base is comprised of more than 200 companies around the world that pay for the African developers Andela selects and trains to work on projects.

The Series D tech-venture is one of Africa’s most visible (by press volume) and best funded ― backed by $181 million in VC from investors that include the Chan Zuckerberg Initiative.

Johnson said the layoffs were not due to a lack of demand or financial woes. That’s probably why Andela released first-time figures of a $50 million run-rate for 2019, something of a rarity for a startup to reach in less than five years. That’s even more rare for ventures in Africa. Only one VC-backed digital company has revealed annual revenues between $50 and $100 million. That’s Jumia, the e-commerce startup that listed in an NYSE IPO earlier this year.

The departing Andela software engineers gained severance packages and are receiving placement assistance from partners including incubators CcHub and iHub.

Chinese mobile phone and device maker Transsion listed in an IPO on Shanghai’s new NASDAQ-like STAR Market, a Transsion spokesperson confirmed to TechCrunch.

Headquartered in Shenzhen, Transsion is a top seller of smartphones in Africa under its Tecno brand. The company has also started to support venture funding of African startups.

Transsion issued 80 million A shares at an opening price of 35.15 yuan (≈ $5.00) to raise 2.8 billion yuan (or ≈ $394 million).

Transsion plans to spend 1.6 billion yuan (or $227 million) of its STAR Market raise on building more phone assembly hubs, and around 430 million yuan ($62 million) on research and development, including a mobile phone R&D center in Shanghai.

Transsion has a manufacturing facility in Ethiopia and announced plans to build an R&D facility in India.

There are a couple things to watch with Transsion’s IPO. First, the public listing, and accompanying capital could mean more venture funding for African startups.

Transsion-funded Future Hub already teamed up with Kenya’s Wapi Capital in August to source and fund early-stage African fintech startups.

Transsion’s IPO and growing presence in Africa also accompanies TechCrunch coverage over the last year that signals China’s growing digital influence in Africa (see Extra Crunch analysis).

More Africa-related stories @TechCrunch

African tech around the ‘net

 

 

 

 

 

 

03 Oct 2019

Africa Roundup: CcHub’s iHub acquisition, Andela’s $50M run-rate and layoffs, Transsion’s IPO

Two of Africa’s powerhouse tech incubators joined forces in September. Nigerian innovation center and seed-fund CcHub acquired Nairobi based iHub.

The purchase amount was undisclosed, but CcHub will finance the deal out of its real-estate project to build a new 10-story HQ in Lagos, CcHub CEO Bosun Tijani told TechCrunch.

Details are emerging on how the two entities will operate together, but Tijani noted some degree of autonomy. The names — CcHub and iHub — will remain the same. Tijani is now co-CEO of both organizations.

Nekesa Were continues as iHub managing director. And iHub’s existing programs will remain, with CcHub extending to Kenya some of its existing activities in education, healthcare and governance.

CcHub will also use the iHub addition to expand the investment scope of its Growth Capital Fund.

The acquisition brings together two of Africa’s most powerful tech hubs by membership networks, volume of programs, startups incubated, and global visibility. CcHub and iHub visitors and partnerships span Zuckerberg, Mayer, Facebook, Google, and several African governments.

There’ll be a lot to cover on how this merger shapes up. At a high level, for now, the CcHub-iHub union creates a direct innovation link between two of Africa’s most active markets for VC and startup formation — Nigeria and Kenya .

Africa-focused tech talent accelerator Andela  announced cuts of 400 junior engineers across Kenya,  Uganda and Nigeria just as the startup released first-time earnings figures indicating it will surpass $50 million in revenues for 2019.

On the disjointed news, Andela CEO told TechCrunch the layoffs were due to a shift in market demand for the startup’s more senior developers.

Andela’s client base is comprised of more than 200 companies around the world that pay for the African developers Andela selects and trains to work on projects.

The Series D tech-venture is one of Africa’s most visible (by press volume) and best funded ― backed by $181 million in VC from investors that include the Chan Zuckerberg Initiative.

Johnson said the layoffs were not due to a lack of demand or financial woes. That’s probably why Andela released first-time figures of a $50 million run-rate for 2019, something of a rarity for a startup to reach in less than five years. That’s even more rare for ventures in Africa. Only one VC-backed digital company has revealed annual revenues between $50 and $100 million. That’s Jumia, the e-commerce startup that listed in an NYSE IPO earlier this year.

The departing Andela software engineers gained severance packages and are receiving placement assistance from partners including incubators CcHub and iHub.

Chinese mobile phone and device maker Transsion listed in an IPO on Shanghai’s new NASDAQ-like STAR Market, a Transsion spokesperson confirmed to TechCrunch.

Headquartered in Shenzhen, Transsion is a top seller of smartphones in Africa under its Tecno brand. The company has also started to support venture funding of African startups.

Transsion issued 80 million A shares at an opening price of 35.15 yuan (≈ $5.00) to raise 2.8 billion yuan (or ≈ $394 million).

Transsion plans to spend 1.6 billion yuan (or $227 million) of its STAR Market raise on building more phone assembly hubs, and around 430 million yuan ($62 million) on research and development, including a mobile phone R&D center in Shanghai.

Transsion has a manufacturing facility in Ethiopia and announced plans to build an R&D facility in India.

There are a couple things to watch with Transsion’s IPO. First, the public listing, and accompanying capital could mean more venture funding for African startups.

Transsion-funded Future Hub already teamed up with Kenya’s Wapi Capital in August to source and fund early-stage African fintech startups.

Transsion’s IPO and growing presence in Africa also accompanies TechCrunch coverage over the last year that signals China’s growing digital influence in Africa (see Extra Crunch analysis).

More Africa-related stories @TechCrunch

African tech around the ‘net

 

 

 

 

 

 

03 Oct 2019

Natalist founder Halle Tecco wants to get you pregnant

Halle Tecco is no stranger to conception struggles. The Rock Health founder and former CEO has been public about her journey on social media, including two rounds of IVF, eventually leading to a healthy baby girl. Now, she wants to help others make babies, too.

To get there, Tecco has joined a class of new fertility tech companies that have popped up in the last few years. Taking from her years of experience building Rock Health, she’s now launched a new company called Natalist, which offers conception products “inspired by beauty and backed by science” to help those hoping to get pregnant in the near future.

Screen Shot 2019 10 02 at 2.49.21 PMYou can pick and choose various products in Natalist’s pretty packaging or opt for the basic “Get Pregnant” bundle, which includes 7 ovulation and 3 pregnancy tests, a one-month supply of prenatal vitamins and Omega DHA, plus the company’s Conception 101 book.

Of course, that package merely provides the basics for any healthy woman with a regular period and no other fertility issues — and, besides the book, its all something you could find in your local pharmacy. But, as Tecco was quick to point out, not every woman is keen on going into their local CVS, grabbing a pregnancy test and taking it up to the register. In fact, many women Tecco polled before starting her company mentioned the need in the market for discretion. Buying online from a trusted brand would provide them with both privacy and security in the product.

While Natalist’s first offerings are the minimum for anyone trying to make a baby, Tecco has already raised a cool $5 million to build out products addressing more serious fertility concerns like PCOS and endometriosis, which combined affect one out of every five women in their child bearing years and can make it a lot harder to get pregnant or make a pregnancy stick.

“We plan to use the funding to bring new products to market but we wanted to start with products that are sort of tried and true,” Tecco told Techcrunch, further explaining she’d like to see Natalist be more than just physical products and become more of a platform to help women through their pregnancy journey.

“We really want to have a support platform for women who have questions or concerns, really creating a great customer experience and helping them troubleshoot if things aren’t going the way that they want them to and also arm them with information and knowledge around getting pregnant,” Tecco said.

While she doesn’t see herself creating something like the app Glow, which both offers information and data through various stages of pregnancy and a community of women working on becoming pregnant, she does see the value of collaboration with these types of communities on various fertility apps and would like to reach out to those founders to see if there might be something there they can work on in the future as well.

For those interested in checking out Natalist’s products, the “Get Pregnant” bundle starts at $90 for a one time purchase or $75 per month for the subscription plan. You can also add products from the site a la carte, should you want more tests or vitamins than what’s in the one-month package.

And for those of you TechCrunch readers interested in the funding details, Natalist took in seed money from Collaborative Fund, Cowboy Ventures, Fuel Capital, Rock Health and xFund, as well as several well-known angel investors, including Katrina Lake, Julia Cheek, Christine Lemke, John Doerr, Malay Gandhi, David Vivero, and R. Martin Chavez.

03 Oct 2019

Natalist founder Halle Tecco wants to get you pregnant

Halle Tecco is no stranger to conception struggles. The Rock Health founder and former CEO has been public about her journey on social media, including two rounds of IVF, eventually leading to a healthy baby girl. Now, she wants to help others make babies, too.

To get there, Tecco has joined a class of new fertility tech companies that have popped up in the last few years. Taking from her years of experience building Rock Health, she’s now launched a new company called Natalist, which offers conception products “inspired by beauty and backed by science” to help those hoping to get pregnant in the near future.

Screen Shot 2019 10 02 at 2.49.21 PMYou can pick and choose various products in Natalist’s pretty packaging or opt for the basic “Get Pregnant” bundle, which includes 7 ovulation and 3 pregnancy tests, a one-month supply of prenatal vitamins and Omega DHA, plus the company’s Conception 101 book.

Of course, that package merely provides the basics for any healthy woman with a regular period and no other fertility issues — and, besides the book, its all something you could find in your local pharmacy. But, as Tecco was quick to point out, not every woman is keen on going into their local CVS, grabbing a pregnancy test and taking it up to the register. In fact, many women Tecco polled before starting her company mentioned the need in the market for discretion. Buying online from a trusted brand would provide them with both privacy and security in the product.

While Natalist’s first offerings are the minimum for anyone trying to make a baby, Tecco has already raised a cool $5 million to build out products addressing more serious fertility concerns like PCOS and endometriosis, which combined affect one out of every five women in their child bearing years and can make it a lot harder to get pregnant or make a pregnancy stick.

“We plan to use the funding to bring new products to market but we wanted to start with products that are sort of tried and true,” Tecco told Techcrunch, further explaining she’d like to see Natalist be more than just physical products and become more of a platform to help women through their pregnancy journey.

“We really want to have a support platform for women who have questions or concerns, really creating a great customer experience and helping them troubleshoot if things aren’t going the way that they want them to and also arm them with information and knowledge around getting pregnant,” Tecco said.

While she doesn’t see herself creating something like the app Glow, which both offers information and data through various stages of pregnancy and a community of women working on becoming pregnant, she does see the value of collaboration with these types of communities on various fertility apps and would like to reach out to those founders to see if there might be something there they can work on in the future as well.

For those interested in checking out Natalist’s products, the “Get Pregnant” bundle starts at $90 for a one time purchase or $75 per month for the subscription plan. You can also add products from the site a la carte, should you want more tests or vitamins than what’s in the one-month package.

And for those of you TechCrunch readers interested in the funding details, Natalist took in seed money from Collaborative Fund, Cowboy Ventures, Fuel Capital, Rock Health and xFund, as well as several well-known angel investors, including Katrina Lake, Julia Cheek, Christine Lemke, John Doerr, Malay Gandhi, David Vivero, and R. Martin Chavez.

03 Oct 2019

MyMilk Labs launches Mylee, a small sensor that analyzes breast milk at home

Many expectant mothers are told that breastfeeding will come naturally, but it is often a fraught and confusing experience, especially during the first few weeks after birth. Parents often worry about if their babies are getting enough nutrition or if they are producing enough milk. MyMilk Labs wants to give nursing mothers more information with Mylee, a sensor that scans a few drops of breast milk to get information about its composition and connects to a mobile app. The Israel-based company presented today at Disrupt Battlefield as one of two wild card competitors picked from Startup Alley.

The Mylee launched at Disrupt with a pre-order price of $249 (its regular retail price is $349). Based in Israel, MyMilk Labs was founded in 2014 by Ravid Schecter and Sharon Haramati, who met while working on PhDs in neuroimmunology and neurobiology, respectively, at the Weizmann Institute of Science.

Mylee deviceDuring the company’s stage presentation, Schecter said the device is meant to give mothers and lactation consultants objective information about breast milk.

Breast milk changes in the first days and weeks after birth, progressing from colostrum to mature milk. Mylee scans the electrochemical properties of milk and then correlates that to data points based on MyMilk Labs’ research to calculate where the sample is on the continuum, then tells mothers if their milk is “delayed” or “advanced,” relative to the time that has passed since they gave birth.

The device’s first version is currently in a beta pilot with lactation consultants who have used them to scan milk samples from 500 mothers.

MyMilk Labs already has consumer breast milk testing kits that enable mothers to provide a small sample at home that is then sent to MyMilk Labs’ laboratories for analysis. One is a nutritional panel that gives information about the milk’s levels of vitamins B6, B12 and A, calories and fat percentage, along with dietary recommendations for the mother. Another panel focuses on what is causing breast pain, a frequent complaint for nursing mothers. It tests for bacterial or fungal infections and gives antibiotic suggestions depending on what strains are detected.

Though some doctors believe testing kits are unnecessary for the majority of nursing mothers, there is demand for more knowledge about breastfeeding, as demonstrated by the line-up of breast milk testing kits from MyMilk Labs and competitors like Lactation Labs, Everly Well and Happy Vitals. Haramati said on stage that MyMilk Labs plans to eventually transfer some of the tests’ capabilities to the Mylee.

03 Oct 2019

Molecule.one uses machine learning to make synthesizing new drugs a snap

Say you’re a pharmaceutical company. You’ve figured out that a novel molecule could be effective in treating an illness — but that molecule only exists in a simulation. How do you actually make it, and enough of it, to test in the real world? Molecule.one is a computational chemistry platform that helps bring theoretical substances to life, and it is debuting its product onstage at Disrupt SF Startup Battlefield.

Computational chemistry is, believe it or not, something of a hot ticket right now. The explosion in computing resources over the last decade has made it possible for the extremely complex systems of molecular biology to be simulated in high enough fidelity to produce new drugs and other important substances.

For example, say a company knows that a condition is caused by overproduction of a given protein. By simulating that protein in the soup of the cell environment, computational chemists can also introduce and virtually observe the behavior of thousands or millions of molecules that don’t occur naturally but might, say, lock down those excess proteins and tag them for removal by the cell.

This process of drug discovery has been productive, but unlike in the real world, in a simulation you don’t actually have to make that magical molecule. It’s just a bunch of numbers interacting with other numbers. How can a pharmaceutical company, which may have paid a lot of money for those numbers, turn them into actual molecules? That’s where Molecule.one steps in.

1.4.0 Molecule Dashboard Reaction tree

Essentially, the company has created a software platform that automates the process of getting from chemicals A, B, and C to chemical Z, with the many steps in between accounted for and documented. It’s based on a machine learning system that has ingested millions of patents and known chemical processes, allowing it to connect the dots and propose a method for creating pretty much any complex organic molecule. In other words, once a drug company has the “what” — a molecule or compound that may fight Alzheimer’s — Molecule.one provides the “how.”

Piotr Byrski met co-founder Paweł Włodarczyk-Pruszyński (who goes by Maxus to avoid confusion with COO Paweł Łaskarzewski) while in college, where they studied and did research together, eventually both earning MDs. They discovered a shared aversion to the grunt work of chemistry — beakers, distillates, titration, and so on.

molecule one header

 

“We found out we shared a similar analytical approach to chemistry. A lot of chemists really like the cooking process involved with organic synthesis,” Byrski told me. “I have to say… I never liked it very much. That made me think that there are many things in the everyday life of a chemist that can be automated, and need to be automated.”

“Automating organic synthesis seems like just another difficult automation problem, but it’s one with real effects. Real people are suffering because drugs are coming to the market,” he said. “We thought we could help. So we did some research, and we found that the field is so under-developed —  the direction research is going is completely unsatisfactory. We began market research — we were both first timers so it was pretty new to us at the time — and we found out there was a big market need for this. It wasn’t a scientific discovery that would sit on a shelf, it could be applied today to help multiple industries.”

By the time they were working on this, companies were already applying simulation, and statistical techniques (machine learning is essentially weapon-grade statistical analysis) were already popping up. BenevolentAI started in 2013, Recursion in 2014, Atomwise in 2015; clearly the field was growing, and is still adding new companies, like ReviveMed. But these are mainly focused on the question of new drugs based on simulations.

“They provide a list of maybe tens of thousands of structures to a pharmaceutical company, but the company then needs to actually verify whether the predictions have any real-life backing. For that you need physical access to these molecules — just knowing the structure doesn’t cut it,” said Byrski.

Molecule.one’s system tells them how to manifest these structures.

1.1.1 Molecule Dashboard Compounds

“We are making the whole synthesis pathway, so going from compounds that are available to ones that you want,” said Włodarczyk-Pruszyński. “Along the way we need to solve many problems — there are many reasons why a reaction could fail. We want to tell users how to make compounds with the process with the highest chance of success.”

And succeed they have: “Our system works for structures that have never been seen before by any chemist,” Byrski said.

The obvious question is why these huge pharma companies, with their bottomless pockets and technical expertise, don’t put together their own synthesis platforms. It comes down to people.

“The most important factor is that it’s hard for a pharmaceutical company to hire machine learning specialists who have a deep background in chemistry. Over 90 percent of the people I know that work on this in the pharmaceutical business are chemists who have some training in machine learning. This is a difficult problem that requires coming at it from the opposite direction,” Byrski explained. “Our head of machine learning [Stanislaw Jastrzębski] is a PhD from the computational side, who would normally go to Google, Facebook or Microsoft. We’ve built a team that is unique in how it bridges the computational technology and chemistry.”

The databases used by Molecule.one’s systems, surprisingly, are mostly public. The U.S. Patent office has tons of patents involving chemical processes — some important, some small, some obscure, some obvious, but all verified and presented formally. This was a gold mine sitting in plain sight, Byrski said. Or perhaps a box full of Lego pieces just waiting to be assembled into the right machine.

The main “proprietary” information they used was a private listing of commercially available chemicals and their prices. A molecule may have more than one pathway to reach it, after all, or perhaps thousands, and one might be cheaper than the others or involve fewer toxic reagents.

With strong results from public databases, they have a better chance of getting pharma companies to share their internal databases when signing up for the service.

The actual business is conducted SaaS-wise, naturally, and all the work takes place in the cloud. There’s also an enterprise tier that allows for on-premises operation, for companies that would rather not have their trade secrets anywhere but on company-owned infrastructure.

So far the company has bootstrapped, and currently has about $400K in the bank, which Byrski said should last them well into next year. “The biggest cost is people,” he said. “Developers, designers, chemists. We’re a software business so we don’t have a lot of other costs — we don’t have to hire a lab, for example.” So they are looking for funding to help hire and scale.

It’s not common in Poland to segue directly from medical school into a startup, Byrski admitted. But he and Włodarczyk-Pruszyński felt that this was too significant an opportunity to do good to pass up. With luck their platform will prove as popular as the drug discovery startups that helped make it necessary to invent.

03 Oct 2019

Leo Aerospace provides bespoke rocket launches — from a hot air balloon

The demand for orbital launches is increasing steadily, and the industry is nowhere near keeping up. Leo Aerospace thinks it can help with a launch technique that’s more efficient and requires far less infrastructure than an ordinary rocket: a hot air balloon. With a rocket attached to it, of course. It sounds wacky at first, but it could prove to be an economical and flexible way of getting to orbit.

Leo is originally out of Purdue, one of two such teams on stage this week at Disrupt SF Startup Battlefield. Co-founder and CEO Dane Rudy said they were looking into new and better ways to achieve orbit besides the traditional surface-based rocket approach.

leo j“We found this really elegant solution that was actually tested in a rudimentary way in the 50s by the Air Force, which is launching rockets from an aerostat — a balloon,” he said.

Perhaps used to countering narrowed eyes and barely disguised incredulity at this point, he hastened to follow up.

“It actually worked really well for what it was designed for. The issue they ran into was that the U.S. shifted toward sending people to the Moon — so there just wasn’t a need for that technology in the Apollo program. But the rise in small satellites has created a huge demand tailored to these capabilities,” he said.

It turns out using a balloon has big benefits. A large amount of a rocket’s fuel and engineering is dedicated to pushing it from the ground, where the atmosphere is heaviest, to the thinner upper atmosphere, where drag and other issues are much less of a worry. By going the first few miles straight up in a balloon, much less rocket is needed to get into orbit, since you’re skipping one of the hardest parts.

The technique is more or less exactly what you’d imagine: A large balloon inflates and lifts the payload, a small rocket, to a designated altitude. Once there it aligns itself and… well, lifts off is perhaps the wrong term. But it ignites and exits the atmosphere at a planned trajectory and inserts the payload into orbit.

There are already air-launch systems out there that use planes rather than balloons, presenting their own challenges and advantages. Leo Aerospace’s main draws are flexibility and cost.

“Our system is fully mobile — it doesn’t require any ground infrastructure,” said Rudy. “The whole thing fits into a regular shipping container.”

That means it can take off wherever and, perhaps more importantly, whenever the client chooses.

 

shipping

Right now the launch industry is expanding like crazy, both because of an increase in total launches and the rise of “ride-sharing,” where dozens of payloads share the cost of a single rocket. The cost goes down, but there are serious inconveniences.

“They don’t have much choice in when they launch or what orbit they’re going to. There’s also the complexity of having to ride with a bunch of other payloads on board — you have to compromise on timing and so on,” Rudy said.

While ride-sharing means many payloads will get to space that might not have a few years ago, it also means they might wait for years while the rest of the seats fill up and get ready to roll. With Leo it’s practically Domino’s for orbit.

That’s all great in theory, but the fact is no one has made a balloon-based commercial launch system. When the Air Force did it, it was pretty crude: The rocket was carried in a vertical position and shot right through the balloon when it went up. That kind of rules out reusing the balloon, but Leo’s entire business is founded on reusability, since that brings costs down immensely.

launch regulus

“That was one of the big problems we had to solve — the expense of the balloon itself; helium is expensive, and the envelope [i.e. the balloon material] is expensive and fragile,” said Rudy. “How do we make that zero stage, as we call it, reusable?”

Amazingly, they determined that tough, ripstop nylon and hot air were actually the best solution. It’s remarkably close in principle to an ordinary recreational hot-air balloon, but with the slight difference that it has to fly up to 18 kilometers of altitude and carry a rocket with it.

“The difference is how do you control and command this sort of vehicle, integrate it into airspace, suspend the rocket beneath it and all that,” Rudy said. “All the stuff you have at Vandenberg Air Base for a launch — we have to make all that mobile.”

Mike Mojave Launch 11 of 25

A bit like going from an ordinary car to a self-driving one, Leo’s balloon may be similar to the recreational type in its basic form, but the technical advances are in how it is controlled and tracked. They can adjust for wind, control the yaw and rotation, rise to a very precise altitude, and so on — naturally, all remotely and with partial autonomy.

The rocket doesn’t shoot through its balloon as before, but fires off at a mission-determined angle. 18 km closer to space, with far less air resistance to worry about, the three-stage rocket (two solid, then one non-cryo liquid) can be much smaller and have far less mass — requiring less than half the fuel to lift a given mass to orbit. To be specific, the system is specced to send 33 gross kilograms, 25 kg of payload, to a 550 kilometer orbit — or about twice that to 300 kilometers.

December saw the company performing reduced-scale tests at altitude, an important stepping stone to regulatory approval. The plan is to make their first full-scale suborbital launch next year with their first customer’s payload on board. Orbital launches are planned for 2022.

 

Leo has gotten through December’s tests on a quite barebones budget for a space startup of about $520,000, through TechStars and a grant from the National Science Foundation. That’s great for a foundation, Rudy said, but full-scale tests and an eventual transition to commercial operations will take more than six figures.

An Air Force Small Business Innovation Research grant has opened the door to other government sources, and there’s been interest from that quarter in the non-orbital potential of the system, for instance high-altitude testing, mobile communications infrastructure, and so on. So already there are multiple eggs in multiple baskets — an attractive quality for investors.

“We’ve done all the foundational work,” said Rudy.  “Now it’s just about scaling up.”